AIFinancial Timesabout 2 hours ago
Insilico Medicine Targets $100B Pain Market
1 min read
Insilico Medicine nominated PCC ISM9528, an AI-driven novel candidate for pain management. The company targets the $100 billion market with this small-molecule program. The candidate addresses a significant unmet need in chronic pain treatment.
Level
Hype check
Tap to vote and see what everyone thinks.
Summary by ByteBrief
